Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.47 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | VKORC1 | Q9BQB6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2355103 | 0.88 | LTA4H (0.71) | LTA4HMAOBCYP11B1CYP11B2KDR | |
| SCHEMBL28251912 | 0.78 | LTA4H (0.72) | LTA4HMAOBCYP11B1CYP11B2 | |
| SCHEMBL9341169 | 0.77 | LTA4H (0.50) | LTA4HMAOBCYP11B1CYP11B2SIGMAR1 | |
| SCHEMBL2027109 | 0.76 | LTA4H (0.69) | LTA4HMAOBCYP11B1CYP11B2 | |
| SCHEMBL984055 | 0.74 | LTA4H (0.67) | LTA4HMAOBCYP11B1CYP11B2P2RX4 | |
| SCHEMBL383153 | 0.74 | MEN1 (0.52) | LTA4HMAOBCYP11B1CYP11B2 | |
| SCHEMBL8993257 | 0.74 | LTA4H (0.65) | LTA4H | |
| SCHEMBL3902050 | 0.74 | LTA4H (0.60) | LTA4HMAOBCYP11B1CYP11B2 | |
| SCHEMBL28131051 | 0.74 | LTA4H (0.60) | LTA4HMAOBKDRSIGMAR1 | |
| SCHEMBL12869627 | 0.74 | LTA4H (0.60) | LTA4HMAOBCYP11B1CYP11B2VKORC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531573-B2 | potent, selective and safe inhibitors of the Ca2+-activated potassium channel | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-05-12 | — | — | US | disclosed |
| EP-0918514-B9 | TRIARYL METHANE COMPOUNDS FOR THE TREATMENT OF CANCER, ACTINIC KERATOSIS AND KAPOSI'S SARCOMA | HARVARD COLLEGE (US) | 2006-07-05 | — | — | EP | disclosed |
| EP-0918514-B1 | TRIARYL METHANE COMPOUNDS FOR THE TREATMENT OF CANCER, ACTINIC KERATOSIS AND KAPOSI'S SARCOMA | HARVARD COLLEGE (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20040127464-A1 | Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease | BRUGNARA CARLO (US) | 2004-07-01 | — | — | US | disclosed |
| US-20030119784-A1 | Method for reducing chloride secretion by intestinal epithelial cells in situ: use of triaryl methane compounds | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-06-26 | — | — | US | disclosed |
| US-6495567-B1 | REDUCING CHLORIDE SECRETION; PREVENTING DEHYDRATION, ACIDOSIS, DEATH AND IMPAIRED GROWTH | BETH ISRAEL DEACONESS MEDICAL CENTER | 2002-12-17 | — | — | US | disclosed |
| US-20020119953-A1 | Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease | BRUGNARA CARLO (US) | 2002-08-29 | — | — | US | disclosed |
| US-6331564-B1 | TREATING DIARRHEA CAUSED BY INFLAMMATORY BOWEL DISEASE, AUTOIMMUNE DISEASES SUCH AS LUPUS, GLOMERULONEPHRITIS | ION PHARMACEUTICALS, INC. | 2001-12-18 | — | — | US | disclosed |
| EP-0918514-A4 | TRIARYL METHANE COMPOUNDS FOR SICKLE CELL DISEASE | HARVARD COLLEGE (US) | 2001-05-09 | — | — | EP | disclosed |
| US-6028103-A | Triaryl methane compounds and analogues thereof useful for the treatment or prevention of sickle cell disease or diseases characterized by abnormal cell proliferation | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2000-02-22 | — | — | US | disclosed |
| EP-0918514-A1 | TRIARYL METHANE COMPOUNDS FOR SICKLE CELL DISEASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1999-06-02 | — | — | EP | disclosed |
| WO-1997034589-A1 | TRIARYL METHANE COMPOUNDS FOR SICKLE CELL DISEASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119784-A1 | Method for reducing chloride secretion by intestinal epithelial cells in situ: use of triaryl methane compounds | SLC10A2, VIP, CLCN2 | LTA4H 752/4885MAOB 3895/4885CYP11B1 317/4885 |
| US-20040127464-A1 | Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease | CCNO, HPGDS, TSPO | LTA4H 836/4885MAOB 4667/4885CYP11B1 100/4885 |
| US-20020119953-A1 | Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease | CCNO, HPGDS, TSPO | LTA4H 836/4885MAOB 4667/4885CYP11B1 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.